Last year, the results of the FDA-mandated non-inferiority safety trial of celecoxib were published. Focusing on CV/GI outcomes, it is not a renal trial. This trial has also been reviewed (with a nice visual abstract) in NephJC.
Some basic info about the trial:
- ~24,000 pts with elevated CVD risk and OA (~90%) or RA (~10%) pain were randomized to celecoxib, naproxen, or ibuprofen.
- Mean daily doses: celecoxib ~200 mg, naproxen ~850 mg, ibuprofen ~2000 mg. ~1/2 of patients were also on ASA for CV protection.
- Esomeprazole was given for GI protection though adherence was not reported.
- Baseline mean Cr was 0.9 +/- 0.2 mg/dL. Patients with CR > 1.7 (M), 1.5 (F) were excluded.
- Mean treatment duration 20 +/- 16 months with mean follow-up 34 +/- 13 months.
- ~2/3 stopped drug at some point and ~1/4 were lost in follow-up.
Results: Celecoxib was "non-inferior" in terms of CV risk compared to ibuprofen and naproxen. The primary composite outcome of CVD, MI, CVA happened to 2.3-2.7% of the ITT groups. In other words, celecoxib is not worse for your heart than ibuprofen or naproxen. There may be a reduced risk of serious GI events with celecoxib as well.
3° outcomes included adjudicated “clinically significant renal events," which were:
- Cr ≥2.0 mg/dL with increase of Cr by ≥ 0.7 mg/dL.
- Admission for AKI (doubling Cr, AKI + K > 6, or requiring RRT).
On-Treatment Analysis -- HR for renal outcomes were: celecoxib vs. naproxen 0.66 (0.44-0.97) and celecoxib vs. ibuprofen 0.54 (0.37-0.80).
So celecoxib may be safer from a renal standpoint than ibuprofen or naproxen in patients without baseline CKD. Note the moderate dose of celecoxib used and high rates of drop out. In addition, significant GFR losses over a relatively short period of time (e.g. Cr 0.9 to 1.5) may have been missed.
What about patients with CKD?
Cohort studies in patients with CKD are mixed and limited by the usual concerns. A recently published prospective cohort study of ~4,000 patients with rheumatoid arthritis compared eGFR trajectories in those having taken NSAIDs (~2,700) to NSAID naïve patients (~1,300). NSAID use was not associated with more rapid CKD progression in those with eGFR > 30 (using Cockgroft-Gault) though a very small number of patients with eGFR < 30 did have more rapid progression on NSAIDs.
Importantly, other cohort studies have shown that higher dose NSAID use may be associated with faster GFR decline and that selective COX-2 inhibitors may not be any safer than non-selective NSAIDs. The latter notion may contradict the study discussed above.
NSAIDs can reduce GFR acutely, worsen hypertension, or provoke hyperkalemia. But this is a concern only for a minority of most CKD patients right? Can close monitoring of patients and striving to use the lowest dose reduce our concerns and allow greater use of these effective medications in patients with CKD? Especially in those patients with "lower-risk" CKD? Given our limited options otherwise, I hope so.
For those interested, a recent review in AJKD about pain control in CKD (and a notable response) provide additional information and are worthy reads.
Stanford Nephrology Fellow